The global market for macular degeneration treatments is anticipated to be driven largely by an increase in the prevalence of age-related macular degeneration (AMD). Throughout the projected period, rising patient awareness and more healthcare spending are also expected to propel the worldwide Macular Degeneration Treatment Market. The introduction of innovative treatments for geographic atrophy, wet AMD (wAMD), and late-stage dry AMD therapy (dAMD) is anticipated to grow the age-related macular degeneration market. In the near future, it is projected that drugs like Novartis' brolucizumab, a longer-acting anti-VEGF, Apellis' APL-2, Ophthotech's Zimura, and Apellis' APL-2 would dominate the worldwide macular degeneration therapy market. In particular, it is projected that a significant driver will be the introduction of medications in the AMD market to treat dAMD.
Read more @ https://creativeedge16.blogspot.com/2023/03/macular-degeneration-treatment-market.html
